


Pharma VOICE

THE FORUM FOR THE INDUSTRY EXECUTIVE

100
of the Most
Inspiring People

Also featuring the
RED JACKET AWARDS



Inspiration and Innovation

Inspired leadership and innovative thinking are just two of the ways in which this year's PharmaVOICE 100 can be described. Over the past dozen years we have showcased some of the most well-known names in the industry as well as the unsung heroes, each of whom are committed to making a difference in the lives of patients as well as their employees, colleagues, companies, and communities.



Each and every year, the inspirational stories of the PharmaVOICE 100, as well as our Red Jacket honorees, reaffirm what's good about our industry. This diverse group of individuals is dedicated to moving the needle to improve all aspects of healthcare — from discovery to commercialization to delivery. They are imagining new possibilities and disrupting the status quo through new and enhanced business models with the patient at the center, creating innovative breakthroughs in science and clinical process improvements, developing new ways to communicate and engage, implementing enhanced talent development techniques, and much more. We hope you are inspired to innovate in your own unique way.

These dedicated company leaders, entrepreneurs, change agents, researchers and scientists, clinical experts, regulators, marketers and creative experts, patient advocates, mentors, and technologists are dedicated to innovation, transformation, and evolution. They represent every aspect of the healthcare ecosystem and are united by a common bond: to make a difference.

These 100 individuals as identified by you, our readers, are innovators creating new opportunities and identifying next steps in an effort to shape and evolve the life-sciences industry for sustainable success. They are envisioning new products and companies to address the needs of patients. And they are philanthropists, who are dedicated to paying it forward personally and through their companies.

In addition to the thoughtful profiles showcasing each individual, we have compiled several informative articles that capture these industry leaders' insights on the topics of innovation and the challenges and opportunities they face as leaders. These articles can only be found online in our bonus content; please log onto pharmavoiced.com to read more.

With thousands of nominations to consider, we rely on the personal accounts from you, our readers, that detail the inspirational and innovative nature of these individuals. Thanks to all of you who took time out of your schedules to nominate the individuals who are making a difference to you, our industry, patients' lives, and the companies and organizations that make up our ecosystem. We also want to thank all of our PharmaVOICE 100 honorees and Red Jacket award winners for taking the time to share their personal stories with us. Please join us in extending warm congratulations to this esteemed group of individuals. And join us September 15 in New York to celebrate the accomplishments of our current and past honorees. For more information about this unique event, please go to www.pharmavoiced.com/pharmavoiced-100-celebration-schedule-of-events.

Taren Grom
Editor

*Getting to know...***John W. Hubbard, Ph.D.****TITLE:** President and CEO**COMPANY:** Bioclinica**EDUCATION:** Ph.D., Physiological Psychology and Physiology, University of Tennessee**FAMILY:** Wife of 36 years**HOBBIES:** Martial Arts, 3rd Degree Black Belt and senior instructor, international travel, home improvements, and gardening**BUCKET LIST:** Achieving his 4th Degree Black Belt — Master Level and continuing to travel around the world learning about different cultures**AWARDS/HONORS:** Fellow, American College of Clinical Pharmacology (1994); Accomplished Alumni Award, University of Tennessee (2009); Distinguished Alumnus Award, Department of Psychology, Commencement Speaker, University of Tennessee College of Arts & Sciences (2012); Fred J. Epstein M.D., Lifetime Achievement Award, 11th Annual Dream & Promise Awards Benefit, Children's Brain Tumor Foundation (2013); University of Tennessee Alumni Professional Achievement Award (2014); Award in Appreciation for your Commitment to Pfizer Quality, (2014)**ASSOCIATIONS:** American College of Clinical Pharmacology; American Association for the Advancement of Science; American Society of Clinical Pharmacology and Therapeutics; Drug Information Association; Society of Sigma Xi

Since taking the helm as Bioclinica's president and CEO in January 2015, John Hubbard, Ph.D., has dramatically changed the company under his leadership and is bringing transformative solutions to the industry.

With extensive insight into the complexities inherent in the drug development process, Dr. Hubbard has created an agile organization committed to surfacing — and realizing — new possibilities within R&D. To this end, his strategic vision centers on simplifying the drug development process, shortening cycle times, and reining in rising costs. He believes more needs to be done to break down the barriers across the industry and improve collaboration with patients, investigators, regulators, payers, service providers, and the industry.

Driven to innovate by

CURIOSITY

DR. JOHN HUBBARD

Breaking Down Barriers to Innovation

Positive. Resilient.

Dr. John Hubbard inspires others by leading by example and by empowering teams to achieve beyond what they think is possible.

"Despite years of trying, we still have an industry with multiple siloes — from research, through development and commercialization," he says. "This challenge is now amplified due to extreme commercial pressures across the biopharmaceutical and healthcare ecosystem and the need to accelerate the development of more effective therapies."

Under Dr. Hubbard's stalwart leadership, Bioclinica has grown from its original two divisions to three business segments comprising a total of nine divisions. He expanded the company's solution sets, once focused on eClinical and imaging, into adjacent areas through strategic acquisitions of leading providers in the areas of patient recruitment-retention, postapproval research, clinical site network, safety and regulatory, and financial lifecycle solutions.

In addition to his talent at delivering growth in alignment with industry needs, Dr. Hubbard is equally passionate about innovation and encourages every team member to pursue finding new ways to address the industry's challenges each and every day.

Dr. Hubbard has a history of breaking down the barriers to innovation.

While at Pfizer as senior VP and worldwide head of development operations, Dr. Hubbard directed and oversaw trial operations and management of more than 450 clinical projects a year and spearheaded initiatives to improve the efficiency and productivity in pharma R&D. He served on the executive taskforce that redesigned Pfizer's R&D organization, which ultimately led to a significant improvement in quality and increase in productivity from 2010 to 2014. The challenges Pfizer faced were the need to reduce enterprise R&D costs by \$2 billion, resolve a clinical warning letter, improve GCP data quality, transition from multiple functional service providers to two global CROs, and deliver the development portfolio on time and on budget.

"This was one of the most challenging positions and assignments I have ever had in my 30-year career," he says. "I also found it extremely rewarding working with a great team to achieve these results."

During Dr. Hubbard's more than 11 years as group president of ICON's global clinical research services business, the CRO's largest business division, he achieved a consolidated annual growth rate of 25% to 35%, and revenue grew from \$85 million in 1999 to just under \$1 billion by the end of 2010.

Dr. Hubbard measures success by his influence on the industry, both through the people he has worked with and the results achieved to bring new innovative drugs to the market.

A trusted, well-liked, and respected leader, Dr. Hubbard leads by empowering team members to achieve beyond what they think is possible. Motivation, he believes, comes from enjoying what you do, but also from interactions with others.

"We sometimes forget the impact we have on people, both through the work we do to bring new drugs to market, but also in our daily interactions," Dr. Hubbard says. "Progress is achieved, when people have the freedom to make mistakes and learn through the process. In the long-term, career achievements are about a mix of impact on industry and on people. I would like to be remembered as an innovator and calculated risk-taker who brought improvements to the clinical development process. I would also like to be remembered as a good leader and mentor." **PV**

Who's on the List — 2016

Indexed by Section



Dr. John Hubbard
BioClinica



Jim Robinson
Astellas Pharma US



Dr. Donald Deieso
WIRB-Copernicus Group



Susan Cobian
HYC Health



William King
Zephyr Health



Jean Chitwood
INC Research



Cynthia Dukes
ICON Clinical Research



Dr. Jane Osbourn
MedImmune



Dr. Murray McKinnon
Janssen Research & Development



Elisa Cascade
DrugDev

COMMANDERS & CHIEFS

Julie AdrianChandler Chicco Agency, inVentiv Health
 Mary AndersonOgilvy CommonHealth Medical Education and SCI Scientific Communications & Information
 Dr. Udit Batra MilliporeSigma, the life science business of Merck KGaA
 Nancy Berg International Society for Pharmacoeconomics and Outcomes Research
 Dr. Paul Bolno WAVE Life Sciences
 Mark Bouck TrialCard
 Louis Breton Calimmune
 Tim Davis Exco InTouch
 Dr. Donald Deieso WIRB-Copernicus Group
 Lori Grant Klick Health
 Adele Gulfo Mylan
 Dr. Magali Haas Cohen Veterans Bioscience
 Steve Hamburg Calcium
 Debbie Hart BioNJ
 Dr. John Hubbard BioClinica
 Mike Kaufmann Cardinal Health
 Ken Keller Daiichi Sankyo
 Dr. Lorence Kim Moderna Therapeutics
 Joe Kuchta Sandbox
 Brian Loew Inspire
 Juan Mantelle ProSolutus
 Jennifer Matthews The Bloc
 Matt McNally Publicis Health
 Dr. Clive Meanwell The Medicines Company
 Dr. Jules Mitchel Target Health
 Carolyn Morgan precisioneffect
 Dr. Brian Nightengale Xcenda
 Chris Perkin Altasciences Clinical Research
 Fred Petito Guidemark Health
 Jim Robinson Astellas Pharma US
 Julie Ross Advanced Clinical
 Shideh Sedgh Bina Insigniam
 Greg Skaliky inVentiv Health
 Lisa Stockman inVentiv Health
 Heather Torak Evoke Health
 François Torche CluePoints
 Dr. Robert Urban Johnson & Johnson
 Clareece West MedNet Solutions
 Dr. Mike Wilkinson PPD
 Andy Woolf Bionical
 Alex Zaposchny iCardiac Technologies

ENTREPRENEURS

Dr. Lisa Boyette Curable
 Kerrie Brady Centrexion Therapeutics
 Susan Cobian HYC Health
 Gregg Fisher The Stem
 Norm Goldfarb MAGI
 Dr. Kate Hersov Medikidz
 William King Zephyr Health
 Stephany Lapierre tealbook
 Stu Libby Zipdrug
 Dr. Jay Lichter Avalon Ventures
 Michael Marett Confideo
 Rishi Shah ContextMedia:Health

CHANGE AGENTS

Gil Bashe Finn Partners

Deirdre BeVard Nektar Therapeutics
 Brion Brandes Spectra BioPharma Selling Solutions
 Cindy Cetani Novartis International
 Jean Chitwood INC Research
 Dr. Marianne De Backer Johnson & Johnson
 Amy Dowell HCB Health
 Brad Hardy Kowa Pharmaceuticals America
 Dr. Julian Jenkins GlaxoSmithKline
 Alison Little KPMG
 Phil Mann MicroMass Communications
 April Mulrone Medidata Solutions
 Dr. Bill Trombetta Saint Joseph's University
 Kilian Weiss Veeva Systems

RESEARCHERS & SCIENTISTS

Cynthia Dukes ICON Clinical Research
 Dr. Jesús Gómez-Navarro Takeda Pharmaceuticals
 Dr. Thomas Large Sunovion Pharmaceuticals
 Dr. Murray McKinnon Janssen Research & Development
 Dr. Jane Osbourn MedImmune
 Dr. Robert Willenbacher Janssen Research & Development

CLINICAL EXPERTS

Sandra Chase Continuum Clinical
 Dr. Ubavka DeNoble PAREXEL
 Amy Grahn Horizon Pharma
 Christina Hughes Bracket
 Lindy Jones Quintiles
 Craig Lipset Pfizer
 Dr. Chris Smyth Novella Clinical
 Dr. Philippe Szapary Janssen Research & Development

CREATIVES

Laurie Bartolomeo Dudnyk
 Dr. Edward Nathan PulseCx
 Jeff Perino Triple Threat Communications

MARKETERS

Victoria Noble Shire
 Jason Noto Sunovion Pharmaceuticals
 Michelle Petroff Fingerprint

PATIENT ADVOCATES

Carolyn Dumond Myriad Genetic Laboratories
 Kelli Duprey Boehringer Ingelheim
 Chemelle Evans Snow Companies
 Lise Hall AstraZeneca
 Nicole Hebbert ... United BioSource Corporation (UBC)
 Valerie Kobzjej Celgene
 Dr. Caroline Kurtz Ironwood Pharmaceuticals

MENTORS

Brian Goff Baxalta
 Dr. Catherine Sohn Sohn Health Strategies
 Dr. Stuart Sowder Pfizer

TECHNOLOGISTS

Sam Anwar eClinical Solutions
 Elisa Cascade DrugDev
 Justin Freid CMI/Compass



info@bioclinica.com